Combined spironolactone and converting-enzyme inhibitor therapy for refractory heart failure.
Three cases are described of severe congestive heart failure which failed to respond to digitalis, high doses of loop diuretics, and converting-enzyme inhibitors. The addition of spironolactone produced a substantial diuresis associated with clinical and radiological improvement in each case. Although a reversible deterioration in renal function was observed, this drug combination represents a therapeutic option in end-stage heart failure.
D000328:Adult; D002216:Captopril / Q000008:administration & dosage; D004231:Diuresis; D004359:Drug Therapy, Combination; D004656:Enalapril / Q000008:administration & dosage; D005260:Female; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000008:administration & dosage* / Q000627:therapeutic use; D013148:Spironolactone / Q000008:administration & dosage* / Q000627:therapeutic use; D013722:Teprotide
D009842:Oligopeptides; D013148:Spironolactone; D004656:Enalapril; D002216:Captopril; D013722:Teprotide